Compare Nucor Corporation (NUE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs GeneDx Holdings Corp — how do they compare? Nucor Corporation trades at $250.23 (market cap $55.84B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Nucor Corporation is far larger — about 27.6× GeneDx Holdings Corp's market cap, and Nucor Corporation pays a 0.91% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and GeneDx Holdings Corp for 19 Days on average.
| NUE | WGS | |
|---|---|---|
Market Cap | $55.84B | $2.02B |
Volume | 848,835 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $167.51 |
52-Week Low | $131.78 | $34.51 |
Typical Hold Time | 78 Days | 19 Days |
Enterprise Value | $60.25B | $2.05B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $250.98, up 1.84% on the day, showing resilience amid a mixed technical backdrop. Recent earnings have beaten expectations in Q1 and Q2 2026, though Q4 2025 was a miss. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% for 2025, and analyst consensus is a Moderate Buy with a $266.88 price target. Revenue is projected to grow to $36.1B in 2026, with net income margin improving to 7.98%.
The outlook for NUE is cautiously optimistic, supported by earnings beats and a solid dividend history, but risks include competitive pressures from new steel capacity and volatile steel prices. The stock's current valuation metrics, such as a P/E of 19.64, appear reasonable relative to historical performance, offering potential upside if earnings guidance is met.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
